Assessment of the role of transcript for GATA-4 as a marker of unfavorable outcome in human adrenocortical neoplasms

Table 2 GATA-6, GATA-4, and LHR expression in human adrenocortical tumors

Patient	Tumor Evolution	GATA-6 Expression	GATA-4 Expression	LHR Expression
1	NM	2.43	1.09	0.54
2	NM	3.39	0.60	1.60
3	NM	3.58	1.75	1.60
4	NM	3.45	0.59	1.07
5	NM	3.21	0.05	1.64
6	NM	2.98	0.91	0.69
7	NM	2.59	0	0.83
8	NM	3.19	0.04	1.17
9	NM	2.62	0.70	1.00
10	NM	3.02	0.52	0.54
11	NM	3.45	0.14	3.84
12	NM	2.44	0.62	0.78
13	NM	3.11	0	1.57
14	MR	3.24	0.32	0.41
15	MR	2.30	3.50	0.44
16	MR	1.74	0.01	0.35
17	MR	2.81	2.50	0.41
18	MR	2.14	3.37	1.06
19	MR	2.61	2.17	0.33
20	MR	2.71	2.96	0.50
21	MR	2.83	0.12	0.48
22^a	MR	3.23	0.58	1.76
22^b	MR	2.07	2.23	1.83

Patients are identified as in Table 1. Relative expression levels were calculated normalizing optical densities of GATA-6, GATA-4 and LHR autoradiograms with corresponding cyclophilin densitometric data as described in materials and methods. Samples 22^a and 22^b are tumor specimens removed from left (22^a) and right (22^b) adrenal of the same patient (patient 22, Table 1) NM: non-metastasizing, MR: metastasizing/recurring

ISSN: 1472-6823